HDAC9 and Thrombocytopenia: In a phase I trial, the association between the HDAC inhibitor vorinostat and the mTOR inhibitor ridaforolimus showed signals of efficacy in advanced solid tumors, especially ccRCC, despite thrombocytopenia as a significant toxicity [48].